Bezafibrate pharmacokinetics

However, in a formal study bezafibrate and fenofibrate did not affect the pharmacokinetics or pharmacodynamics of a single dose of repaglinide 0.25 mg (63). 

Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004 58 390-6. 

In a study in healthy subjects bezafibrate 400 mg once daily for 5 days had no effect on the pharmacokinetics of a single 250-microgram dose of repa-glinide, and did not alter the glucose-lowering effect of repaglinide. ... 

The use of bezafibrate with ciclosporin has resulted in significantly increased serum creatinine and reductions, no change, or increased serum ciclosporin levels. The use of fenofibrate has also been associated with reduced renal function and possibly reduced serum ciclosporin levels. Two studies found no pharmacokinetic interaction between ciclosporin and gemfibrozil while a third found gemfibrozil caused a significant reduction in ciclosporin levels. 

Colestyramine does not alter the pharmacokinetics of clofibrate when both drugs are given at the same time. Similarly colestipol does not alter the pharmacokinetics of clofibrate or fenofibrate, and colesevelam does not alter the pharmacokinetics of fenofibrate. Colestipol can reduce the absorption of gemfibrozil if given at the same time, but not if administration is separated by 2 hours. A similar interaction occurs between bezafibrate and colestyramine... 

---